BlackRock Inc. bought a new stake in shares of Biohaven Ltd. (NYSE: BHVN) during the undefined quart

Its partner is South Korean peer SK Biopharmaceuticals. It also secured a victory in a lawsuit.

Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a ke

Biohaven secures a transformative $795M global licensing deal with SK Biopharmaceuticals for its Kv7

Biohaven stock rallies 18% on a $795M out-licensing deal granting SK Biopharmaceuticals global right

Biohaven Ltd. (NYSE:BHVN) scored two major wins this week. The company signed a lucrative licensing

Biohaven gains $795M in global licensing deal and $4M lawsuit win. BHVN jumps 13% as William Blair e

Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular ses

JOYY Inc (NASDAQ: JOYY) reported Q2 earnings below estimates, but beat revenue expectations. Shares

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion

Biohaven has ​entered into ‌a licensing agreement ​with ​South Korean drug ⁠maker ​SK Biopharmaceuti

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $7

SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $7

 Biohaven Ltd. and/or its wholly owned subsidiaries ("Biohaven") (NYSE:BHVN) and Yale Univer

NEW HAVEN, Conn., Aug. 25, 2026 /PRNewswire/ -- Biohaven Ltd.

Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and raises

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises t

Biohaven (NYSE:BHVN) reported quarterly losses of $(0.78) per share which missed the analyst consens

First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic eff

Infinitum founder and Groq board director brings frontier AI and technology-investing expertise to B

The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade sec

NEW HAVEN, Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd.

Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combina

US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big ga

Biohaven's pipeline is now more focused after having to narrow down its R&D efforts to other assets.

David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery Bruce Car, Ph.D.

Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discover

Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-li

Biohaven Ltd. (NYSE:BHVN) shares fell Monday after Bank of America Securities (BofA) downgraded the

Biohaven (BHVN) shares fall as BofA downgrades the stock to Underperform, citing a risky profile ahe

U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Mon

US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol

B of A Securities analyst Jason Gerberry downgrades Biohaven (NYSE:BHVN) from Neutral to Underper

BHV-1300 is the first MoDE extracellular protein degrader, a novel small molecule IgG1, 2 and 4 degr

BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a ne

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company f

Biohaven Ltd. (NYSE: BHVN) ("Biohaven") a global clinical-stage biopharmaceutical company fo

HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and m

Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discove

Morgan Stanley analyst Terence Flynn maintains Biohaven (NYSE:BHVN) with a Overweight and lowers

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and lowers t

https://www.sec.gov/Archives/edgar/data/1935979/000162828026029834/biohavens-3asr.htm

Citigroup analyst Samantha Semenkow maintains Biohaven (NYSE:BHVN) with a Buy and raises the pric

Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa a

TD Cowen analyst Tyler Van Buren maintains Biohaven (NYSE:BHVN) with a Buy and raises the price t

Biohaven shares rose in premarket trading after Xenon's Phase 3 epilepsy study showed strong sei

HC Wainwright & Co. analyst Douglas Tsao maintains Biohaven (NYSE:BHVN) with a Neutral and lo

RBC Capital analyst Leonid Timashev maintains Biohaven (NYSE:BHVN) with a Outperform and raises t

Biohaven (NYSE:BHVN) reported quarterly losses of $(1.21) per share which missed the analyst consens